With its first-in-class endothelin and angiotensin II receptor antagonist Filspari, Travere Therapeutics is providing a more ...

The race is on to develop therapeutic cancer vaccines that could give immunotherapies an edge, and late-stage trials could ...

Amylyx’s recent decision to withdraw its ALS drug Relyvrio from the market highlights an important business decision for ...

The FDA is looking at five big decision deadlines in the coming three weeks, including two for a CAR-T therapy and another ...

While these technologies are now a therapeutic reality, the ASGCT 2024 annual meeting this week was a reminder of just how ...

Anticipating approval for its COPD therapy ensifentrine, Verona has entered into a $650 million financing deal with Oaktree ...

Launched in 2021, the public-private consortium on Wednesday updated ASGCT attendees on its efforts to bring adeno-associated ...

Novavax Soars on $1.4B Deal With Sanofi for COVID Vaccine - read this article along with other careers information, tips and ...

With its $525 million investment, Royalty Pharma will acquire the royalties and milestones for ImmuNext’s anti-CD40 therapy ...

ASGCT 2024 session, CBER Director Peter Marks made the case for a better, “more convergent” global framework on cell and gene ...

Takeda saw a 57% drop in profit in its 2023 fiscal year and has lowered its outlook for the coming fiscal year, mostly driven ...

Jeffrey Chamberlain, president of the American Society of Gene & Cell Therapy, spoke with BioSpace about what we can expect ...